Vector Biopharma kicks of with CHF30m Series A financing
With a Series A funding of CHF 30m from Versant Ventures, Vector Biopharma AG set out to solve several of the current gene delivery problems.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1300 entries already.
Entries by Thomas Gabrielczyk
Two deaths with Novartis gene therapy
/in News/by Thomas GabrielczykSwiss-headquarterd Novartis AG has reported two cases of fatal liver failure after treatment with the gene therapy Zolgensma.
Azenta set to acquire B Medical Systems
/in News/by Thomas GabrielczykAzenta Inc has entered into an agreement to acquire B Medical Systems S.á r.l. and its subsidiaries for 410m.
Sartorius pays £415m for Albumedix Ltd
/in News/by Thomas GabrielczykSartorius Stedim Biotech has purchased the world’s largest human albumin producer Albumedix to broaden its product portfolio in animal-free cell media and to stabilise protein drugs.
BioNtech SE expands collab with Genmab A/S
/in News/by Thomas GabrielczykAs Genmabs Hexabody tumour antibody platform is advancing, BioNTech has secured a licence in the field of immunotherapy to co-develop antibodies on 50:50 base.
F2G to use $70m financing to advance olorofilm
/in News/by Thomas GabrielczykBritish antifungal developer F2G Ltd has announced a $70mn financing round to push development of its late-stage compound olorofilm.
Sosei announces $1.2bn R&D collaboration with Abbvie
/in News/by Thomas GabrielczykSosei Heptares and AbbVie have inked a multi-target licence option drug discovery agreement in neurology.
UK-Spanish team to optimise efficacy of microbial production processes
/in News/by Thomas GabrielczykResearchers have presented a novel method to promote biofilm formation and thus to increase efficiency of biocatalysis in biotech production.
InflaRX set to file for MAA for vilobelimab
/in News/by Thomas GabrielczykInflaRx plans to apply for Emergency Use Authorization from the US FDA in Q3/2022 for vilobelimab, the company’s treatment for critically ill COVID-19 patients.
New antibody cocktail might fight all corona variants
/in News/by Thomas GabrielczykA nasal antibody cocktail binding to the conserved S2 stalk region of SARS-COV-2 might end the corona pandemic.